FDA approves pancreatic cancer drug early after trials show nearly doubled survival
Approval came more than six months early after trials showed median survival of 13.2 months versus 6.7 months with chemotherapy.
The U.S. Food and Drug Administration has approved a breakthrough drug for the most common form of pancreatic cancer more than six months ahead of schedule, offering what officials described as unprecedented survival rates for patients with limited options.